Orgenesis Inc. Goodwill and Intangible Assets (Total)

Goodwill and Intangible Assets (Total) of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Goodwill and Intangible Assets (Total) growth rates and interactive chart. The sum of goodwill and all other intangible assets. Intangible assets are items that a company owns and derives benefit from, but is unable to physically measure and count. Examples of intangible assets include patents, trademarks and copyrights. Goodwill is a special type of intangible asset that normally appears in a company's balance sheet following a business combination. When the fair value of the consideration paid by the purchaser for an entity exceeds the fair value of the net assets they have acquired, the purchaser must recognize the resulting difference as goodwill in their balance sheet.


Highlights and Quick Summary

  • Goodwill and Intangible Assets (Total) for the quarter ending June 29, 2021 was $21 Million (a -1.14% decrease compared to previous quarter)
  • Year-over-year quarterly Goodwill and Intangible Assets (Total) increased by 169.53%
  • Annual Goodwill and Intangible Assets (Total) for 2020 was $21.8 Million (a 166.76% increase from previous year)
  • Annual Goodwill and Intangible Assets (Total) for 2019 was $8.16 Million (a -74.39% decrease from previous year)
  • Annual Goodwill and Intangible Assets (Total) for 2018 was $31.9 Million (a 0.0% decrease from previous year)
Visit stockrow.com/ORGS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Goodwill and Intangible Assets (Total) of Orgenesis Inc.

Most recent Goodwill and Intangible Assets (Total)of ORGS including historical data for past 10 years.

Interactive Chart of Goodwill and Intangible Assets (Total) of Orgenesis Inc.

Orgenesis Inc. Goodwill and Intangible Assets (Total) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $21.03 $21.28
2020 $21.77 $7.8 $7.7 $7.67 $21.77
2019 $8.16 $28.75 $30.46 $30.83 $8.16
2018 $31.87 $33.21 $24.56 $26.09 $31.87
2017 $25.74 $26.16 $25.02 $0.0 $25.74
2016 $24.63 $24.63 $0.0 $0.0 $24.63
2015 $26.18 $26.19
2014 $0.0
2013 $0.0
2012 $0.0 $0.0

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.